BCTX ▲ +5.5% - BriaCell Therapeutics Corp.
$BCTX BCTXW BCTXZ BCTXL - Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
BriaCell Therapeutics shares rose 5.5% after its Data Safety Monitoring Board recommended continuing the company's Phase 3 trial of its metastatic breast cancer treatment, signaling the independent panel found no safety concerns warranting a halt to the study. The DSMB clearance to proceed is a positive milestone for the trial's advancement toward potential regulatory approval.
14-SEP-2026 07:30 AM ET
Share this post
More filings for $BCTX
View full $BCTX filing history →💬 Comments
Loading comments…
Leave a comment
